1. Home
  2. VRAX vs EZRA Comparison

VRAX vs EZRA Comparison

Compare VRAX & EZRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virax Biolabs Group Limited

VRAX

Virax Biolabs Group Limited

HOLD

Current Price

$2.76

Market Cap

2.3M

Sector

Health Care

ML Signal

HOLD

Logo Reliance Global Group Inc. Common Stock

EZRA

Reliance Global Group Inc. Common Stock

N/A

Current Price

$2.31

Market Cap

2.1M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
VRAX
EZRA
Founded
2013
2013
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Specialty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.3M
2.1M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
VRAX
EZRA
Price
$2.76
$2.31
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$1.00
N/A
AVG Volume (30 Days)
65.5K
3.9M
Earning Date
06-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
85.79
EPS
N/A
N/A
Revenue
N/A
$12,430,959.00
Revenue This Year
$217,274.83
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.10
$0.11
52 Week High
$13.19
$5.45

Technical Indicators

Market Signals
Indicator
VRAX
EZRA
Relative Strength Index (RSI) 48.51 47.45
Support Level $2.55 $2.03
Resistance Level $3.10 $4.02
Average True Range (ATR) 0.18 0.41
MACD -0.07 0.03
Stochastic Oscillator 42.61 20.00

Price Performance

Historical Comparison
VRAX
EZRA

About VRAX Virax Biolabs Group Limited

Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.

About EZRA Reliance Global Group Inc. Common Stock

Reliance Global Group Inc operates as a holding company that acquires, owns, and actively manages insurance and technology-focused businesses. The company focuses on growing by pursuing acquisition strategies initially, and focuses on wholesale and retail insurance agencies. Its primary move is to identify specific risks to reward arbitrage opportunities and develop these on a national platform, thereby increasing revenues and returns, and then identify and acquire undervalued wholesale and retail insurance agencies with operations in growing or underserved segments, expand and optimize their operations. The Company operates as a single operating segment, the Insurance Segment, earning its revenues from insurance commissions.

Share on Social Networks: